



8 OCTOBER 2008

Results update  
International Study  
**INTERPHONE**  
International Agency for Research on Cancer

**INTERPHONE Study**  
radiofrequency radiation

–

–

[Redacted text block]

–

[Redacted text block]

[REDACTED]

[REDACTED]

.

•

[REDACTED]

•

-

occupational exposure to EMF (

Table 1 – Summary of published results from national INTERPHONE analyses of mobile phone use

Study	Country	Age range	Age (years)	Number of cases and controls	OR and 95% CI for Regular use	OR and 95% CI for 10+ years or more in the past	OR and 95% CI for 10+ years use, start of use 10+ years in past	OR and 95% CI for 10+ years use 10+ years in past
<b>Glioma</b>								
Denmark (Christensen et al., 2005)	Denmark	20-59	2000-2002	81 cases, 155 controls	Low-grade: 1.08 (0.58, 2.00) High-grade: 0.58 (0.37, 0.90)	Low-grade: 1.08 (0.58, 2.00) High-grade: 0.48 (0.19, 1.16)	NA	NA
France (Hours et al., 2007)	France	30-59	2001-2003	96 cases, 96 controls	1.15 (0.65, 2.05)	1.06 (0.74, 1.52)	NA	NA
Germany#	Germany	30-69	2000-2002	104 cases, 104 controls	1.03 (0.75, 1.42)	1.03 (0.75, 1.42)	NA	NA
Japan (Takekoshi et al., 2008)	Japan	30-69	2000-2004	83 cases, 163 controls	1.22 (0.63, 2.37)	1.22 (0.63, 2.37)	6.5 years + 0.60 (0.20, 1.78)	7
Norway (Klaabae et al., 2007)	Norway	18-69	2001-2002	289 cases, 358 controls	0.67 (0.4, 0.9)	0.67 (0.4, 0.9)	6+ years 0.8 (0.5, 1.2)	70
Sweden (Lonnrot et al., 2005)	Sweden	20-69	2000-2002	157 cases, 157 controls	0.7 (0.3, 1.16)	0.7 (0.3, 1.16)	NA	0.8
<b>Meningioma</b>								
Denmark (Christensen et al., 2004)	Denmark	20-59	2000-2002	106 cases, 212 controls	0.96 (0.51, 1.57)	0.96 (0.51, 1.57)	0.22 (0.04, 1.11)	NA
France (Hours et al., 2007)	France	30-59	2001-2003	109 cases, 214 controls	0.92 (0.53, 1.59)	0.92 (0.53, 1.59)	46 months + NA	NA
Germany#	Germany	30-69	2000-2002	104 cases, 104 controls	1.03 (0.75, 1.42)	1.03 (0.75, 1.42)	NA	NA
Japan (Takekoshi et al., 2008)	Japan	30-69	2000-2004	128 cases, 229 controls	0.74 (0.42, 1.16)	0.74 (0.42, 1.16)	6+ years + 1.09 (0.59, 2.04)	30
Norway (Klaabae et al., 2007)	Norway	18-69	2001-2002	207 cases, 258 controls	0.88 (0.5, 1.1)	0.88 (0.5, 1.1)	6+ years 1.2 (0.6, 2.3)	17
Sweden (Lonnrot et al., 2005)	Sweden	20-69	2000-2002	223 cases, 62 controls	0.7 (0.3, 1.16)	0.7 (0.3, 1.16)	NA	0.8
<b>Acoustic neuroma</b>								
Denmark (Christensen et al., 2004)	Denmark	20-59	2000-2002	106 cases, 212 controls	0.96 (0.51, 1.57)	0.96 (0.51, 1.57)	0.22 (0.04, 1.11)	NA
France (Hours et al., 2007)	France	30-59	2001-2003	109 cases, 214 controls	0.92 (0.53, 1.59)	0.92 (0.53, 1.59)	46 months + NA	NA

Country	Age range	Diagnosis years	Number of cases and controls	OR and 95% CI Ever regular use	OR and 95% CI Start of use 10 years or more in the past	OR and 95% CI Ipsilateral use, start of use 10+ years in past	OR and 95% CI Contralateral use, start of use 10+ years in past
				# cases	# cases	# cases	# cases
Germany (Schlehofer et al., 2007)	30-69	2000-2003	97 194	0.67 (0.38, 1.19) 29	0.66 (0.28, 1.57) 14	NA 0	NA
Japan (Takahashi et al., 2006)	30-59	2000-2004	101 339	0.73 (0.43, 1.23) 51	0.79 (0.24, 2.65) 22	NA	NA
Norway (Kilbuck et al., 2007)	6+ years	6+ years	4	0.8 (0.2, 2.5) 4	0.5 (0.2, 1.0) 22	0.5 (0.2, 1.0) 22	0.5 (0.2, 1.0) 22
Sweden (Lenn et al., 2008)	30-69	1999-2002	148 684	1.0 (0.6, 1.7) 69	1.0 (0.6, 1.7) 69	1.0 (0.6, 1.7) 69	1.0 (0.6, 1.7) 69
Norway (Sjoholm et al., 2005)	1999-2004	1999-2004	678 2,553	0.9 (0.7, 1.1) 360	0.9 (0.7, 1.1) 360	0.9 (0.7, 1.1) 360	0.9 (0.7, 1.1) 360
<b>Parotid gland tumours</b>							
Israel (Sadetzki et al., 2007)	1981-2001	1981-2001	460 1,266	0.87 (0.68, 1.13) 13	0.87 (0.68, 1.13) 13	0.87 (0.68, 1.13) 13	0.87 (0.68, 1.13) 13
Sweden and Denmark (Lenn et al., 2006)	20-69	2000-2002	102 321	0.9 (0.5, 1.5) 6	0.9 (0.5, 1.5) 6	0.9 (0.5, 1.5) 6	0.9 (0.5, 1.5) 6
<b>Total</b>							
285	0.86 (0.42, 1.77)	13	1.60 (0.68, 3.72)	10	0.58 (0.15, 2.32)	3	0.58 (0.15, 2.32)
252	Total - regular use only	13	1.60 (0.68, 3.72)	10	0.58 (0.15, 2.32)	3	0.58 (0.15, 2.32)
33	Benign	7	2.6 (0.9, 7.9)	6	0.3 (0.0, 2.3)	1	0.3 (0.0, 2.3)
77	Malignant	6	0.7 (0.1, 5.2)	4	0.7 (0.1, 5.2)	2	0.7 (0.1, 5.2)

## Publications

l'étude IN

—



